Mucosal exposure to antigen: Cause or cure of type 1 diabetes?

Current Diabetes Reports

Volumn 7, Issue 2, 2007, Pages 91-98

  Fousteri, Georgia ^a   von Herrath, Matthias ^b   Bresson, Damien ^b  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4 INTEGRIN; CD3 ANTIBODY; CD4 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD8 ANTIGEN; DNA VACCINE; FOOD ANTIGEN; GAMMA INTERFERON; GLUTAMATE DECARBOXYLASE 65; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; GLUTAMATE DECARBOXYLASE 67; HEAT SHOCK PROTEIN 60; HUMAN INSULIN; INSULIN; INSULIN ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; L SELECTIN; MAJOR HISTOCOMPATIBILITY ANTIGEN; PIG INSULIN; PLACEBO; PROINSULIN; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR; UNINDEXED DRUG;

ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; AUTOIMMUNITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DIABETOGENESIS; DISEASE COURSE; DISEASE RESISTANCE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPOGLYCEMIA; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; IMMUNOREACTIVITY; IMMUNOTHERAPY; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINE FLORA; INTESTINE MUCOSA; MONOTHERAPY; MUCOSAL IMMUNITY; NONHUMAN; PREDICTION; PRIMARY PREVENTION; REGULATORY T LYMPHOCYTE; REVIEW; RISK REDUCTION; TH1 CELL; TH2 CELL;

ANIMALS; ANTIGENS; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNITY, MUCOSAL; IMMUNOTHERAPY; INSULIN; MUCOUS MEMBRANE;

EID: 34248370977     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-007-0017-3     Document Type: Review

References (67)

1. Neutra MR, Mantis NJ, Kraehenbuhl JP: Collaboration of epithelial cells with organized mucosal lymphoid tissues. Nat Immunol 2001, 2:1004-1009.
2. von Herrath MG: Design of immune-based interventions in autoimmunity and viral infections - the need for predictive models that integrate time, dose and classes of immune responses. Novartis Found Symp 2001, 239:16-24; discussion 24-30, 45-51.
3. O'Shea JJ, Ma A, Lipsky P: Cytokines and autoimmunity. Nat Rev Immunol 2002, 2:37-45.
4. Cheroutre H: Starting at the beginning: new perspectives on the biology of mucosal T cells. Annu Rev Immunol 2004, 22:217-246.
5. Neutra MR, Kozlowski PA: Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006, 6:148-158.
6. Faria AM, Weiner HL: Oral tolerance. Immunol Rev 2005, 206:232-259.
7. Harrison LC, Hafler DA: Antigen-specific therapy for autoimmune disease. Curr Opin Immunol 2000, 12:704-711.
8. Miller JF: Autoantigen-induced deletion of peripheral self-reactive T cells. Int Rev Immunol 1995, 13:107-114.
9. Schwartz RH: Models of T cell anergy: is there a common molecular mechanism? J Exp Med 1996, 184:1-8.
10. Ohashi PS, DeFranco AL: Making and breaking tolerance. Curr Opin Immunol 2002, 14:744-759.
11. Sakaguchi S, Sakaguchi N, Asano M, et al.: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995, 155:1151-1164.
12. Roncarolo MG, Gregori S, Battaglia M, et al.: Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 2006, 212:28-50.
13. Weiner HL: Oral tolerance: immune mechanisms and the generation of Th3-type TGF-beta-secreting regulatory cells. Microbes Infect 2001, 3:947-954.
14. Bisikirska B, Colgan J, Luban J, et al.: TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest 2005, 115:2904-2913.
15. Cobbold S, Waldmann H: Infectious tolerance. Curr Opin Immunol 1998, 10:518-524.
16. Nakayama M, Abiru N, Moriyama H, et al.: Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 2005, 435:220-223.
17. Lernmark A, Agardh CD: Immunomodulation with human recombinant autoantigens. Trends Immunol 2005, 26:608-612.
18. Bach JF, Koutouzov S, van Endert PM: Are there unique autoantigens triggering autoimmune diseases? Immunol Rev 1998, 164:139-155.
19. Tuohy VK, Yu M, Yin L, et al.: The epitope spreading cascade during progression of experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol Rev 1998, 164:93-100.
20. Tian J, Gregori S, Adorini L, et al.: The frequency of high avidity T cells determines the hierarchy of determinant spreading. J Immunol 2001, 166:7144-7150.
21. Dai YD, Carayanniotis G, Sercarz E: Antigen processing by autoreactive B cells promotes determinant spreading. Cell Mol Immunol 2005, 2:169-175.
22. Wong FS: Insulin - a primary autoantigen in type 1 diabetes? Trends Mol Med 2005, 11:445-448.
23. Oling V, Marttila J, Ilonen J, et al.: GAD65- and pro-insulin-specific CD4+ T-cells detected by MHC class II tetramers in peripheral blood of type 1 diabetes patients and at-risk subjects. J Autoimmun 2005, 25:235-243.
24. Arif S, Tree TI, Astill TP, et al.: Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest 2004, 113:451-463.
25. Zhang ZJ, Davidson L, Eisenbarth G, et al.: Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci U S A 1991, 88:10252-10256.
26. Bergerot I, Arreaza GA, Cameron MJ, et al.: Insulin B-chain reactive CD4+ regulatory T-cells induced by oral insulin treatment protect from type 1 diabetes by blocking the cytokine secretion and pancreatic infiltration of diabetogenic effector T-cells. Diabetes 1999, 48:1720-1729.
27. Homann D, Dyrberg T, Petersen J, et al.: Insulin in oral immune "tolerance": a one-amino acid change in the B chain makes the difference. J Immunol 1999, 163:1833-1838.
28. Ma SW, Zhao DL, Yin ZQ, et al.: Transgenic plants expressing autoantigens fed to mice to induce oral immune tolerance. Nat Med 1997, 3:793-796.
29. Ma S, Huang Y, Yin Z, et al.: Induction of oral tolerance to prevent diabetes with transgenic plants requires glutamic acid decarboxylase (GAD) and IL-4. Proc Natl Acad Sci U S A 2004, 101:5680-5685.
30. Bergerot I, Ploix C, Petersen J, et al.: A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes. Proc Natl Acad Sci U S A 1997, 94:4610-4614.
31. Shreedhar VK, Kelsall BL, Neutra MR: Cholera toxin induces migration of dendritic cells from the subepithelial dome region to T- and B-cell areas of Peyer's patches. Infect Immun 2003, 71:504-509.
32. Ploix C, Bergerot I, Durand A, et al.: Oral administration of cholera toxin B-insulin conjugates protects NOD mice from autoimmune diabetes by inducing CD4+ regulatory T-cells. Diabetes 1999, 48:2150-2156.
33. Aspord C, Czerkinsky C, Durand A, et al.: alpha4 integrins and L-selectin differently orchestrate T-cell activity during diabetes prevention following oral administration of CTB-insulin. J Autoimmun 2002, 19:223-232.
34. Bellmann K, Kolb H, Rastegar S, et al.: Potential risk of oral insulin with adjuvant for the prevention of Type I diabetes: a protocol effective in NOD mice may exacerbate disease in BB rats. Diabetologia 1998, 41:844-847.
35. Blanas E, Carbone FR, Allison J, et al.: Induction of autoimmune diabetes by oral administration of autoantigen. Science 1996, 274:1707-1709.
36. Hanninen A, Braakhuis A, Heath WR, et al.: Mucosal antigen primes diabetogenic cytotoxic T-lymphocytes regardless of dose or delivery route. Diabetes 2001, 50:771-775.
37. Hanninen A, Martinez NR, Davey GM, et al.: Transient blockade of CD40 ligand dissociates pathogenic from protective mucosal immunity. J Clin Invest 2002, 109:261-267.
38. Ke Y, Kapp JA: Oral antigen inhibits priming of CD8+ CTL, CD4+ T cells, and antibody responses while activating CD8+ suppressor T cells. J Immunol 1996, 156:916-921.
39. Garside P, Steel M, Liew FY, et al.: CD4+ but not CD8+ T cells are required for the induction of oral tolerance. Int Immunol 1995, 7:501-504.
40. von Herrath MG, Coon B, Wolfe T: Tolerance induction with agonist peptides recognized by autoaggressive lymphocytes is transient: therapeutic potential for type 1 diabetes is limited and depends on time-point of administration, choice of epitope and adjuvant. J Autoimmun 2001, 16:193-199.
41. von Herrath MG, Dyrberg T, Oldstone MB: Oral insulin treatment suppresses virus-induced antigen-specific destruction of beta cells and prevents autoimmune diabetes in transgenic mice. J Clin Invest 1996, 98:1324-1331.
42. Bregenholt S, Wang M, Wolfe T, et al.: The cholera toxin B subunit is a mucosal adjuvant for oral tolerance induction in type 1 diabetes. Scand J Immunol 2003, 57:432-438.
43. Homann D, Holz A, Bot A, et al.: Autoreactive CD4+ T cells protect from autoimmune diabetes via bystander suppression using the IL-4/Stat6 pathway. Immunity 1999, 11:463-472.
44. von Herrath MG, Whitton JL: DNA vaccination to treat autoimmune diabetes. Ann Med 2000, 32:285-292.
45. Li AF, Escher A: Intradermal or oral delivery of GAD-encoding genetic vaccines suppresses type 1 diabetes. DNA Cell Biol 2003, 22:227-232.
46. van den Engel NK, an Haack M, Martin S, et al.: Oral DNA vaccination with a plasmid encoding soluble ICAM-1 modulates cytokine expression profiles in nonobese diabetic mice. J Mol Med 2002, 80:301-308.
47. Harrison LC, Dempsey-Collier M, Kramer DR, et al.: Aerosol insulin induces regulatory CD8 gamma delta T cells that prevent murine insulin-dependent diabetes. J Exp Med 1996, 184:2167-2174.
48. Aspord C, Thivolet C: Nasal administration of CTB-insulin induces active tolerance against autoimmune diabetes in non-obese diabetic (NOD) mice. Clin Exp Immunol 2002, 130:204-211.
49. Daniel D, Wegmann DR: Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc Natl Acad Sci U S A 1996, 93:956-960.
50. Yuki Y, Hara-Yakoyama C, Guadiz AA, et al.: Production of a recombinant cholera toxin B subunit-insulin B chain peptide hybrid protein by Brevibacillus choshinensis expression system as a nasal vaccine against autoimmune diabetes. Biotechnol Bioeng 2005, 92:803-809.
51. Alleva DG, Gaur A, Jin L, et al.: Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide. Diabetes 2002, 51:2126-2134.
52. Chen W, Bergerot I, Elliott JF, et al.: Evidence that a peptide spanning the B-C junction of proinsulin is an early Autoantigen epitope in the pathogenesis of type 1 diabetes. J Immunol 2001, 167:4926-4935.
53. Martinez NR, Augstein P, Moustakas AK, et al.: Disabling an integral CTL epitope allows suppression of autoimmune diabetes by intranasal proinsulin peptide. J Clin Invest 2003, 111:1365-1371.
54. Every AL, Kramer DR, Mannering SI, et al.: Intranasal vaccination with proinsulin DNA induces regulatory CD4+ T cells that prevent experimental autoimmune diabetes. J Immunol 2006, 176:4608-4615.
55. Tian J, Clare-Salzler M, Herschenfeld A, et al.: Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice. Nat Med 1996, 2:1348-1353.
56. Bresson D, Togher L, Rodrigo E, et al.: Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest 2006, 116:1371-1381.
57. Ostroukhova M, Seguin-Devaux C, Oriss TB, et al.: Tolerance induced by inhaled antigen involves CD4(+) T cells expressing membrane-bound TGF-beta and FOXP3. J Clin Invest 2004, 114:28-38.
58. Sherry NA, Tsai EB, Herold KC: Natural history of beta-cell function in type 1 diabetes. Diabetes 2005, 54(suppl 2): S32-S39.
59. Sosenko JM, Palmer JP, Greenbaum CJ, et al.: Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2006, 29:643-649.
60. Skyler JS, Krischer JP, Wolfsdorf J, et al.: Effects of oral insulin in relatives of patients with type 1 diabetes: the Diabetes Prevention Trial - Type 1. Diabetes Care 2005, 28:1068-1076.
61. Pozzilli P, Pitocco D, Visalli N, et al.: No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group. Diabetologia 2000, 43:1000-1004.
62. Chaillous L, Lefevre H, Thivolet C, et al.: Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabete Insuline Orale group. Lancet 2000, 356:545-549.
63. Harrison LC, Honeyman MC, Steele CE, et al.: Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes. Diabetes Care 2004, 27:2348-2355.
64. Metzler B, Wraith DC: Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity. Int Immunol 1993, 5:1159-1165.
65. Kupila A, Sipila J, Keskinen P, et al.: Intranasally administered insulin intended for prevention of type 1 diabetes - a safety study in healthy adults. Diabetes Metab Res Rev 2003, 19:415-420.
66. Liu E, Moriyama H, Abiru N, et al.: Anti-peptide autoantibodies and fatal anaphylaxis in NOD mice in response to insulin self-peptides B:9-23 and B:13-23. J Clin Invest 2002, 110:1021-1027.
67. Bielekova B, Goodwin B, Richert N, et al.: Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000, 6:1167-1175.